Tradestie Institutional Equity Comparison Engine

BGM vs BHST โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BGM Overall Edge

BGM Captures Institutional Edge (1โ€“1 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to BGM Group Ltd. Class A Ordinary Shares (BGM) driven by superior Momentum & Technical while BHST counters with relative strength in Growth & Margin. Fundamentally, BGM trades at N/M Forward P/E with -23.4% operating margin (+69.8% YoY revenue) versus BHST at N/M Forward P/E and -18.0% operating margin (+3.8% YoY). In options structure, BGM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against BHST sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
BGM N/M vs BHST N/M Fwd P/E
Growth & Margin Winner BHST
Op Margin -23.4% vs -18.0% ยท YoY +69.8% vs +3.8%
Momentum & Technical Winner BGM
1Y -17.5% vs -79.4% ยท 52W Pos 74% vs 6%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
BGM NASDAQ
BGM Group Ltd. Class A Ordinary Shares
Pharmaceutical Preparations
$8.00
-1.6% 1D
Market Cap $108.6M
1M Return -21.57%
1Y Return -17.53%
Forward P/E N/M
Unified AI Score
59.6 / 100 HOLD
Tech 65.0 Fund 55.0 Flow 50.0 Mom 50.0
BHST NASDAQ
BioHarvest Sciences Inc. Common Stock
Pharmaceutical Preparations
$1.30
-1.52% 1D
Market Cap $29.9M
1M Return -22.62%
1Y Return -79.4%
Forward P/E N/M
Unified AI Score
58.2 / 100 HOLD
Tech 75.0 Fund 57.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BGM -17.53% BHST -79.4% Spread: +73.31 pp (BGM Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
BGM TTM Op. Margin: -23.4% BHST TTM Op. Margin: -18.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BGM vs BHST. Trailing 12-month operating profitability (BGM -23.4% vs BHST -18.0%) and valuation multiples (BGM N/M vs BHST N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BGM (6) vs BHST (2)
Institutional Metric BGM BHST Criterion Row Winner
Market Capitalization Scale $108.6M $29.9M Larger Scale BGM
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +69.8% +3.8% Higher Growth BGM
Operating Margin (TTM) Profitability -23.4% -18.0% Higher Margin BHST
Net Profit Margin Profitability -44.2% -31.2% Higher Margin BHST
Return on Equity (ROE) Capital Efficiency -7.4% -142.5% Higher ROE BGM
52-Week Range Position Momentum 74% ($0โ€“$11) 6% ($1โ€“$7) Stronger Trend BGM
Beta / 30D Volatility Risk Regime 3.69ฮฒ ยท 80% Vol 0.25ฮฒ ยท 86% Vol Lower Realized Risk BGM
Unified Institutional Score Composite Signal 59.6 / 100 (HOLD) 58.2 / 100 (HOLD) Higher Composite BGM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BGM vs BHST Buy Guide
BGM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BGM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BHST UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BHST Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BGM nor BHST registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.